Christie's is a British auction house founded in 1766 by James Christie. Its main premises are on King Street, St James's in London, at Rockefeller Center in New York City and at Alexandra House in Hong Kong. It is owned by Groupe Artémis, the holding company of François-Henri Pinault. Sales in 2015 totalled £4.8 billion (US$7.4 billion). In 2017, the Salvator Mundi was sold for $400 million at Christie's in New York, at the time the highest price ever paid for a single painting at an auction.
pre|CISION® peptide drug conjugates comprise a peptide moiety bound to a payload by a linker that is specifically cleaved by FAP, a protease selectively overexpressed in the tumor microenvironment (TME) of many solid tumors. The pre|CISION® peptide moiety prevents cellular entry of the conjugate unless cleaved by FAP, enabling targeted delivery of released payload directly to tumors. Two payloads are described using this platform: AVA6000 (doxorubicin [dox]; pre-clinical and clinical) and AVA6103 (exatecan, pre-clinical). Methods: Pharmacokinetic (PK; plasma and intra-tumoral) parameters of the conjugate and released payload were investigated pre-clinically (for both AVA6000 and AVA6103) in tumor-bearing mice. Clinical validation was sought for AVA6000 given intravenously q2w or q3w in a first-in-human, 3+3 dose escalation Phase 1 trial exploring the safety, PK and preliminary efficacy. Preclinical data with both AVA6000 and AVA6103 demonstrate substantial tumor-specific payload release, with high tumor-to-plasma ratios ranging from 10:1 to > 200:1 indicating selective release and uptake within the tumor. Preliminary analysis of PK data with AVA6103 in murine models demonstrated a differentiated PK profile versus AVA6000 with sustained payload release in the tumor (tumor:plasma of 10:1 longer than 24 hours) with no systemic exatecan exposure beyond 4 hours. In the Phase 1 trial of AVA6000, 63 patients received escalating doses of AVA6000 from 80mg/m2 (equivalent to 54 mg/m2 dox) to 385 mg/m2 (260 mg/m2 dox) with no MTD identified in the trial. Importantly, of the 63 patients dosed, 53 patients received molar equivalent doses of dox higher than the conventional 75 mg/m2 dose. PK proof of principle was demonstrated in patients treated with AVA6000, with elevated released tumor dox concentrations (median tumor:plasma 100:1 at 24 hours post first dose) and lower plasma Cmax of released dox (77.9-92.5% reduction). The AUC of released dox was lower (4.8-77%) across dose levels when compared with published data for conventional dox (75 mg/m2). In addition, released dox had a 40% lower volume of distribution and a >40% increase in plasma elimination half-life compared with conventional dox (75 mg/m2, historical data). Clinical toxicities were reduced relative to historical data and preliminary signals of efficacy were seen, including a disease control rate of 90% in patients with salivary gland cancers (n=10) treated at >250 mg/m2 doses. In the Phase 1 trial, AVA6000 exhibits promising tumor-targeting characteristics with encouraging clinical activity and reduced systemic toxicities validating the tumor-specific FAP cleavage mode of action. These AVA6000 data along with the preclinical PK data with AVA6103 have informed the predictive modeling to support the clinical development of AVA6103 by optimizing the delivery of the exatecan payload. Gezim Lahu, Udai Banerji, William C. Tap, Natalie Cook, Jeff T. Evans, Ruth Plummer, Alan Anthoney, Christopher Plummer, Rhona Dawson, Paul Loadman, Huw Jones, Nelson Kinnersley, Ruairidh Edwards, Curtis Rink, Ellen Watts, Gilad Gordon, Lee D. Cranmer, Chris Twelves. Comparative pharmacokinetics and tumor activation of fibroblast activation protein (FAP)-enabled pre|CISION® peptide drug conjugates [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT151.
Background Since the transition from paper prescribing charts to electronic there has been an ongoing issue with STAT medications being prescribed under the 'once only' tab frequently being left unadministered. This can effect patient care. Existing prompts appear on the electronic chart but it is felt that nursing staff have become 'numb' to these. This QIP aims to improve the administration of medicines that have been prescribed as once only and also improve the rate of documentation as to why they are not administered at St Gemma's Hospice. The intervention trialled was to write when a once only medication had been prescribed on treatment room white boards (viewed very regularly by nursing staff) as an additional means of communication. Methods Data was collected retrospectively between December 2022 and January 2023 including the number of once only prescriptions, the number not administered and the number unadministered with documented reasons for this. Interviews were conducted with nursing teams and themes surrounding this issue were identified. The intervention and education on this were implemented in February and the same parameters re-audited in March and April. Results 75% of nurses felt the main issue was lack of communication between prescribers and nursing team and 100% of nurses felt the proposed intervention would be helpful. In the months prior to the intervention only 75–80% of unadminsitered prescriptions had reasons for this documented. At the end of the two month intervention trial 82% of once only medications were administered and reason documentation rates for those left unadminsitered improved to 100%. Conclusion This QIP recommends long term adoption of this intervention to improve patient care. Barriers to success identified included 'change over' of junior doctors on rotation thus it is also recommended to discuss this during the induction of new doctors to the Hospice.
Department of Life Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel (Portillo M, Toiber D) The Zlotowski Center for Neuroscience, Ben- Gurion University of the Negev, Beer Sheva, Israel (Portillo M, Toiber D) Correspondence to: Debra Toiber, [email protected]. Received January 16, 2023 Received in revised form March 14, 2023 Accepted March 26, 2023 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The traditional system of medical education was a structure and process-based system with limited assessment of application of knowledge, skills, and attitudes. Decades after the World Health Organization gave preliminary guidelines on Competency-based medical education (CBME) in 1978, countries around the world are still taking to the newer medical education systems. In India, CBME replaced traditional system of medical education in 2019 while the National Medical Council replaced Medical Council of India in 2020. The annual intake of medical undergraduates has reached an all-time high of one lakh students per year in India and our medical education system is taking baby steps toward CBME. The implementation of CBME poses different hurdles for medical educators as well as medical students. Medical educators are yet to develop confidence in the newer teaching learning methods (e.g., Small Group Teaching, Role-play, Peer group learning etc.), along with the array of newer assessment methods. There in lies an immense and urgent need of training medical educators with continued hand holding along with adapting newer teaching learning methods to the students of generation Z who are tech-savvy but anxious and indulged yet stressed. This review has tried to articulate the current situation of CBME in the world and in India, acceptance of CBME by faculty and students and the way forward for India's medical education system.
Since prehistorical times, the traditional knowledge of medicinal plants has been prevalent in India. The Indian Himalayas are one of the mega-biodiversity regions with vast reserves of medicinal plants. In dermatology, advanced healthcare solutions are not ordinarily available in rural areas; therefore, traditional medicines are used in treatment. The present review aims to emphasize and enlist the details of medicinal plants with curative action against skin disease in the Indian Himalayan region and to draw the attention of pharmacologists, botanists, and phytochemists to conduct scientific research on important ethno-dermatological medicinal plants. The review aimed to analyze the data of 112 plants from 56 families obtained from various online databases and servers. Lamiaceae and Asteraceae represent the highest number of plants against skin disorders. Leaves (44%) were the most commonly used plant part and the mode of administration of plant extract was majorly external and very few orally. The herbal formulations for skin by different cosmetic industries were studied individually to find out their key bioactive ingredients and were further listed in a table. In herbal cosmetics, Centella asiatica (L.) Urb. extract, sandalwood oil, and Aloe vera (L.) Burm. f leaf pulp are used in most herbal products because of their skin rejuvenating properties. The Indian Himalayas are the treasure box of medicinal plants but, because of increased environmental degradation, the number of plant species is declining. This review on ethno-dermatological knowledge of medicinal plants can escalate the development of drugs and new therapeutic potentials for curing skin diseases.